Similar A1C Outcomes in Type 1 Diabetic Patients Undergoing Intensive Diabetes Management With Preprandial Rapid-Acting Insulin and Either CSII or Glargine
- Anne Peters Harmel, MD and
- Ruchi Mathur, MD
- From the Department of Endocrinology, University of Southern California, Los Angeles, California
- Address correspondence to Dr. Anne Harmel, Endocrinology, University of Southern California, 2905 Alma Ave., Manhattan Beach, CA 90266. E-mail: momofmax{at}hotmail.com
The importance of achieving and maintaining tight glycemic control in patients with type 1 diabetes is well known (1). Continuous insulin infusion therapy (CSII) has been available for many years, but only recently have reports of efficacy with rapid-acting insulin analogues been published. Similarly, multiple daily injection (MDI) therapy using glargine insulin in conjunction with premeal rapid-acting insulin is relatively new (2).
In our diabetes center, all patients with type 1 diabetes receive …
